Floatz Rating
CC43/100
Confidence
Indicative
Sponsor
M.D. Anderson Cancer Center
Modality
Cell therapy
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
33Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06237881CT.gov A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73Moderate confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Lung Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Ksq-001Ex (this asset) | M.D. Anderson Cancer Center | P1/2 | CC · 43 |
| Carboplatin | Nanfang Hospital, Southern Medical University | P4 | BB |
| Belagenpumatucel-L (Sk-Lu-1) | NovaRx Corporation | P3 | BB |
| Nivolumab | Hospital Israelita Albert Einstein | P2 | BB |
| Icotinib | Fuda Cancer Hospital, Guangzhou | P4 | BB |
| Pralsetinib, Trans- | Hoffmann-La Roche | P3 | BB |
| Cyclophosphamide | Pfizer | P3 | BB |
| Rivoceranib | Fuzhou General Hospital | P3 | BB |
| Trastuzumab | Cancer Research UK | P2/3 | B |
+39 more in the Lung Neoplasm cohort
Other indications for Ksq-001Ex
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Head And Neck Neoplasm | — | P1/2 | CC · 45 |
| Melanoma | — | P1/2 | CC · 41 |
| Cancer | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Ksq-001Ex in Lung Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/ksq-001ex-lung-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →